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Abstract
Purpose The aim of this study was to investigate the time- and dose-dependency of DNA double-strand break (DSB) induction
and repair in peripheral blood leucocytes of prostate cancer patients during therapy with 177Lu-PSMA.
Methods Blood samples from 16 prostate cancer patients receiving their first 177Lu-PSMA therapy were taken before and at
seven time-points (between 1 h and 96 h) after radionuclide administration. Absorbed doses to the blood were calculated using
integrated time–activity curves of the blood and the whole-body. For DSB quantification, leucocytes were isolated, fixed in
ethanol and immunostained withγ-H2AX and 53BP1 antibodies. Colocalizing foci of both DSBmarkers were manually counted
in a fluorescence microscope.
Results The average number of radiation-induced foci (RIF) per cell increased within the first 4 h after administration, followed
by a decrease indicating DNA repair. The number of RIF during the first 2.6 h correlated linearly with the absorbed dose to the
blood (R2 = 0.58), in good agreement with previously published in-vitro data. At late time-points (48 h and 96 h after adminis-
tration), the number of RIF correlated linearly with the absorbed dose rate (R2 = 0.56). Inmost patients, DNADSBswere repaired
effectively. However, in some patients RIF did not disappear completely even 96 h after administration.
Conclusion The general pattern of the time- and dose-dependent induction and disappearance of RIF during 177Lu-PSMA
therapy is similar to that of other radionuclide therapies.
Keywords DNA double-strand breaks . γ-H2AX . 53BP1 . Biodosimetry . Absorbed dose to the blood . Prostate cancer .
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Introduction
Membrane glycoprotein prostate-specific membrane antigen
(PSMA) is highly overexpressed in prostate cancer and me-
tastases, making it a particularly suitable target for imaging
and therapeutic agents [1, 2]. For the last 5 years, PSMA-
binding ligands labelled with the β-particle-emitter 177Lu
have been used in an increasing number of medical centres
worldwide for the treatment of metastatic castration-resistant
prostate cancer. Various studies have shown promising results
including high response rates, a favourable safety profile
and reduction in pain [3–8]. However, the ionising ra-
diation from 177Lu not only destroys malignant tissue,
but also leads to DNA damage in healthy cells. In particular,
the haematopoietic system is an organ-at-risk for targeted ra-
dionuclide therapies. As the absorbed dose to the blood can be
used as a surrogate marker for the absorbed dose to the bone
marrow, the quantification of radiation-induced DNA damage
in blood and its correlation with the absorbed dose to the
blood is of great interest [9].
Among the different types of DNA damage, double-strand
breaks (DSBs) are the most critical lesions, since they are
difficult to repair, and misrepair can lead to mutations or cell
death. DNA DSBs can be visualized by immunofluorescence
staining with antibodies for γ-H2AX and 53BP1 [10–12]. The
microscopically visible colocalizing γ-H2AX + 53BP1 foci in
the cell nuclei can then be quantified to assess DNA DSB
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damage. Since these foci appear with the induction of DNA
DSBs and disappear with the progression of DSB repair, they
can be used to describe the time-dependency of DNA damage
induction and repair during irradiation [13–16].
So far, only a few studies have investigated radiation-
induced DNA damage during radionuclide therapy by quan-
tifying γ-H2AX foci or colocalizing γ-H2AX + 53BP1 foci.
Three studies have addressed focus formation during
radioiodine therapy [9, 15, 17]. Two studies analysed the ki-
netics of focus formation during peptide receptor radionuclide
therapy with 177Lu-labelled DOTA-D-Phe-Tyr3-octreotate
(177Lu-DOTATATE) and 177Lu-labelled DOTA-D-Phe-Tyr3-
octreotide (177Lu-DOTATOC) [14, 18]. Despite the increasing
number of radionuclide therapies, DNA damage in blood
leucocytes of patients during therapy with PSMA-binding li-
gands has not been investigated until now.
Therefore, the aim of the present study was to investigate
the time- and dose-dependency of DSB induction and repair in
blood leucocytes of prostate cancer patients during their first
therapy cycle with 177Lu-PSMA.
Materials and methods
Patients
The study included 16 prostate cancer patients (P1–P16) re-
ceiving their first treatment with 177Lu-PSMA. A standard
activity of 6 GBq of a PSMA ligand (PSMA I&T;
SCINTOMICS GmbH, Munich, Germany) labelled with
177Lu (EndolucinBeta®; ITM Isotopen Technologien
München AG, Munich, Germany) was intravenously admin-
istered over 20min. The end of the administration process was
chosen as the starting and reference point for this study. The
patients were hospitalized for 2 days after the start of the
treatment. All patients underwent a diagnostic PET/CT scan
with a 68Ga-labelled PSMA ligand for uptake detection and
staging/restaging of the disease and a MAG3 scan with 99mTc
before and after therapy to assess kidney function. Serum PSA
levels were also determined before and after therapy. Therapy
response was evaluated based on the imaging results, accord-
ing to the modified PET Response Criteria in Solid Tumors
(mPERCIST) and RECIST1.1 [19, 20], and changes in serum
PSA levels, in analogy to the PCWG3 criteria [21].
Blood sampling
Blood samples were taken prior to administration (t0; for deter-
mination of the individual number of baseline foci) and nomi-
nally at 1 h (t1), 2 h (t2), 3 h (t3), 4 h (t4), 24 h (t5), 48 h (t6) and
96 h (t7) after administration. Blood was drawn using lithium-
heparin blood-collecting tubes (S-Monovette®; Sarstedt,
Nümbrecht, Germany). Due to variations in the management
of the individual patients, there were occasional deviations from
the nominal sampling time-points. The last blood sample (96 h
after administration) was missing in patients P5, P8 and P12. In
patient P11, the t3 sample could not be evaluated.
Activity quantification
An aliquot of each blood sample was measured in a calibrated
high-purity germanium detector (Canberra, Rüsselsheim,
Germany). The counting efficiency of the detector was
ascertained bymeasuring several NIST- andNPL-traceable stan-
dards. For activity quantification, the γ-emission line of 177Lu at
208.4 keV (emission probability of 10.4%) was evaluated. The
measured number of counts was decay-corrected to the start time
of the measurement, and the corresponding activity value was
then decayed to the time-point of the blood sampling.
Evaluation of DNA damage: γ-H2AX + 53BP1 assay
The blood samples were processed and the γ-H2AX + 53BP1
foci evaluated following the protocol described by Eberlein
et al. [22]. Briefly, leucocytes were separated by density cen-
trifugation in BD Vacutainer CPT tubes (BD, Heidelberg,
Germany), washed, fixed in 70% ethanol and stored at
−20 °C. For immunofluorescence staining and focus analysis
[23], the samples were shipped to the Bundeswehr Institute of
Radiobiology in Munich, Germany. In each sample, γ-
H2AX + 53BP1 colocalizing foci in 100 cells were counted.
In a small number of samples, up to 200 cells were counted.
To determine the average number of radiation-induced foci
(RIF) per cell, the number of individual baseline foci per cell
was subtracted from the number of counted foci per cell in all
samples taken after administration of the radiopharmaceutical.
Measurement of whole-body retention
External dose-rate measurements and whole-body gamma cam-
era scans (e.cam; Siemens Healthineers, Erlangen, Germany)
were performed to determine the whole-body activity retention.
For the dose-rate measurements, a ceiling-mounted shielded sur-
vey meter (automess – Automation und Messtechnik GmbH,
Ladenburg, Germany) fixed 2.5 m above the patient’s bed was
used. At least seven measurements were taken in each patient.
On the first day,measurements were taken directly (3min up to a
maximum of 38 min) after administration, prior to the first
postadministration void or defaecation by the patient, and then
approximately 2 h, 4 h and 7 h after administration, followed by
three more measurements every 12 h on the subsequent days.
All measurement data were normalised to the first initial mea-
surement. The whole-body gamma camera scans were per-
formed nominally 4 h, 24 h, 48 h and 96 h after administration.
The last whole-body scan (96 h after administration) was miss-
ing in patients P5, P8 and P12. In patient P5, a whole-body scan
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approximately 68 h after administration was performed instead.
Additionally, all patients underwent a SPECT/CT scan (Symbia
T2 or Symbia Intevo Bold; Siemens Healthineers, Erlangen,
Germany) either 24 h or 48 h after administration. To avoid
the possible effects of the radiation from the CT scan on the
focus count, blood samples were always taken before the
SPECT/CT scan.
The count rates in counts per second were evaluated in the
anterior and the posterior image of each whole-body scan
using syngo.via software (Siemens Healthineers, Erlangen,
Germany). The geometric mean of the background-corrected
anterior and posterior count rate was then calculated. The val-
ue for the first time-point of the external dose-rate measure-
ment was decay-corrected to the time of administration and
normalised to 1, corresponding to 100% uptake. To combine
the dose-rate measurements and the whole-body scan data, the
count rates obtained from imaging performed 4 h after admin-
istration were normalised to the corresponding external dose-
rate value 4 h after administration.
Calculation of the absorbed doses to the blood
using time-integrated activity coefficients
Triexponential and biexponential fit functions were used to
describe the time curves for the activity retention in the blood
and in the whole-body, respectively, in each patient. By inte-
grating the time-activity functions over time up to the time-
point t of the respective blood withdrawal, time-integrated
activity coefficients (TIACs) for the activity concentration in
the blood (τml of bl(t) in hours per millilitre) and for the whole-
body (τwb(t) in hours) were obtained.
The absorbed doses to the bloodDbl(t) as a function of time
were calculated as described by Eberlein et al. [14].
Additionally, the injection phase over the first 20 min with
patient-specific TIAC values τml of bl,i for the blood contribu-
tion and τwb,i for the whole-body contribution was considered
in this study, as the activity was administered using a syringe
pump over 20 min. The constant TIAC values τml of bl,i and
τwb,i were calculated assuming a linear uptake for −20 min < t
< 0 until the values of τml of bl (t = 0) and τwb (t = 0), respec-
tively, were reached. This resulted in the following equation
describing the absorbed dose to the blood:
Dbl tð Þ ¼ A0  ð85:3 Gy ml








GBq  h  τwb tð Þ þ τwb; i
 Þ
ð1Þ
where A0 is the administered activity in gigabecquerels and wt
is the weight of the patient in kilograms. A derivation of Eq. 1
and a detailed description of the constants therein is given in
the Supplementary Material of reference [14].
The absorbed dose rate dDbldt is defined as the derivative of
the absorbed dose to the blood Dbl (Eq. 1) over time.
Statistical analysis
OriginPro 2017 (OriginLab Corporation) was used for data
analysis, plotting and statistical evaluation. To test whether
data were normally distributed, the Shapiro-Wilk test was
used. For correlation analysis, Pearson correlation was applied
for normally distributed datasets and Spearman correlation
was applied if datasets were not normally distributed.
Results were considered significant for p < 0.05. To test for
differences between two groups of normally distributed
data, t-tests were used. Results were considered signifi-
cant for Prob>|t| < 0.05. The standard deviation of the
focus count was calculated for each evaluated blood
sample assuming a Poisson distribution of the counts
in 100 cells. For the calculation of the standard devia-
tion of the average number of RIF per cell, the standard
deviation of the baseline focus count was considered
additionally and error propagation was performed.
Generally, the standard deviation is stated for all mean




A total of 16 heavily pretreated patients (P1–P16) aged be-
tween 54 and 81 years (average 70 ± 9 years) were enrolled.
The mean administered activity was 5.9 ± 0.2 GBq of 177Lu.
The demographic and clinical data of all patients are presented
in Table 1.
The pretreatments included surgery (radical prostatectomy/
prostatovesiculectomy, lymphadenectomy, orchiectomy),
external-beam radiation therapy, therapy with 223Ra
dichloride, therapy with LHRH agonists and antagonists
(leuprorelide, degarelix), antiandrogen therapy with
abiraterone, bicalutamide, enzalutamide and flutamide, che-
motherapy (docetaxel, cabazitaxel) and therapy with
denosumab. All patients had a diagnostic PET/CT scan with
68Ga-labelled PSMA 7 to 106 days before the start of therapy
and again 39 to 114 days after therapy. Additionally, all pa-
tients underwent 99mTc-MAG3 scintigraphy 3 to 31 days be-
fore the start of therapy. Only in patients P2 and P4 was the
MAG3 scan (with <100 MBq 99mTc) performed on the day of
therapy, at least 3 h before administration of 177Lu-labelled
PSMA. Of the 16 patients, 15 (all except P2) presented with
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bone metastases and 12 (all except P3, P7, P10 and P14)
presented with lymph node metastases. Three patients (P8,
P9 and P16) additionally had liver metastases. P9 also had
metastases in the pleura, adrenal gland and muscles. After
the first therapy cycle, four patients showed a partial response,
three patients showed stable disease, five patients showed
progressive disease, and two patients showed a mixed re-
sponse. Two patients (P8 and P16) died after the first therapy
cycle.
Dosimetry
A triexponential fit function was used to describe the activity
retention in the blood. For describing the whole-body reten-
tion, a biexponential fit function sufficed to describe the ki-
netics as, in most patients, this resulted in the same curve but
revealed smaller errors in the fit parameters than the
triexponential fit function. With the corresponding TIAC
values, which were obtained by integrating the time-activity
functions over time up to the time-point t of the respective
blood withdrawal, the absorbed doses to the blood were cal-
culated according to Eq. 1. Consequently, the absorbed doses
represent cumulative doses from the start of administration to
the respective time-point t.
The absorbed dose to the blood directly after administration
(after the 20 min injection time) was 3.2 ± 0.6 mGy on aver-
age. The average total absorbed dose to the blood, which was
calculated by integrating to t =∞, was 109 ± 28 mGy. The
minimal total absorbed dose to the blood was 76 mGy (P3
and P11) and the maximal total absorbed dose to the blood
was 164 mGy (P9). The average absorbed doses to the blood
at t1, t2, t3 and t4 were 17 ± 6 mGy, 27 ± 7 mGy, 34 ± 8 mGy
and 40 ± 9 mGy, respectively. For the later time-points, differ-
ences in the kinetics among the patients increased and values
for the absorbed doses to the blood were no longer significant-
ly drawn from a normally distributed population. The median
absorbed doses to the blood at t5, t6 and t7 were 71 mGy (min
52 mGy, max 129 mGy), 80 mGy (min 61 mGy, max
144 mGy) and 88 mGy (min 69 mGy, max 155 mGy), respec-
tively. At t7, in all patients except P9, more than 80% of the
total absorbed dose to the blood was reached. In patient P9,
the absorbed dose to the blood at this time-point was only 56%
of the calculated total absorbed dose to the blood.
Figure 1a shows the absorbed doses to the blood as a func-
tion of time in five selected patients. Patient P1 can be con-
sidered typical with a total absorbed dose to the blood of
103 mGy and a characteristic time-dependent curve. Patient
P8 showed a similar time-dependency of the absorbed dose to
the blood. Patient P9 showed a much slower and longer in-
crease in the absorbed dose to the blood as a function of time
compared with that in most of the other patients. Patients P13
and P14 also showed similar time-dependency of the absorbed
dose to the blood. Patients P10 and P11 showed the maximal
(155 mGy) and minimal (69 mGy) absorbed doses to the
blood at the last sampling time-point, respectively.
The corresponding time-dependency of the absorbed dose
rate dDbldt is shown in Fig. 1b in the same five patients. In all
patients, the average absorbed dose rates at t1, t2, t3, t4, t5, t6
and t7 were 11.59 ± 2.98 mGy h
−1, 7.83 ± 2.11 mGy h−1, 6.03
± 1.85 mGy h−1, 4.84 ± 1.57 mGy h−1, 0.72 ± 0.26 mGy h−1,
0.29 ± 0.14 mGy h−1 and 0.14 ± 0.10 mGy h−1, respectively.
At the last sampling time-point t7, the absorbed dose rate was
below 0.20 mGy h−1 in all patients except P9 (0.41 mGy h−1),
P13 (0.26 mGy h−1) and P14 (0.25 mGy h−1).
DNA damage foci
The average number of foci per cell at baseline was 0.32 ± 0.11.
Paired sample t-tests showed that the number of foci per cell at
baseline was significantly different from the values at all later
time-points t1 to t7. The individual baseline value in each pa-
tient was subtracted from the number of foci for all time-points
after administration to calculate the average number of RIF per
cell. The average numbers of RIF per cell over all patients at t1,
t2, t3, t4, t5, t6 and t7 were 0.29 ± 0.14, 0.39 ± 0.15, 0.38 ± 0.09,
0.38 ± 0.17, 0.27 ± 0.13, 0.21 ± 0.14 and 0.10 ± 0.13, respec-
tively. The individual data for all patients are shown in Fig. 2.
Generally, the average number of RIF increased or
remained constant from t1 to t4. This increase in the average
number of RIF was significant from time-point t1 to t2, but not
from t2 to t3 or from t3 to t4. Only in one patient (P8) was a
continuous decrease in the average number of RIF observed
during the first 4 h after administration, starting directly after
the first time-point with 0.38 ± 0.12 RIF per cell to 0.03 ± 0.10
RIF per cell at t4 (Fig. 1c). Starting from time-point t4, the
average number of RIF significantly decreased at all consec-
utive time-points. At the last time-point t7, 96 h after admin-
istration, in seven of 13 patients (P1, P2, P3, P4, P6, P11 and
P15) the average number of foci per cell had decreased to the
individual baseline values, while in six patients (P7, P9, P10,
P13, P14 and P16) the number of foci was still elevated. In
three patients (P7, P9 and P14), the number of RIF per cell
was still above 0.2 at this time-point. As an example, the
average number of RIF per cell as a function of time in P9,
the patient with the highest value (0.38 ± 0.10) at t7, are shown
in Fig. 1c (blue diamonds).
Dose-dependency of the number of RIF per cell
Figure 3 shows the average number of RIF per cell as a func-
tion of the absorbed dose to the blood in all 16 patients. A
linear dependency of the absorbed dose to the blood Dbl and
the average number of RIF per cell was assumed for the first
three time-points (t0, t1 and t2; up to 2.6 h after administration).
The corresponding dose range is shown in detail in Fig. 3b.
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The patient data for these time-points were pooled and a linear
fit to the pooled data was performed (R2 = 0.583) resulting in
the linear equation:
Average RIF per Cell
¼ 0:0336 0:0258ð Þ þ 0:0122 0:0015ð Þ mGy−1  Dbl
ð2Þ
Fig. 2 Average number of RIF per cell as a function of time after administration of 177Lu-PSMA. a Overview of all time-points. b Detailed view of the
first five time-points (nominally 0 to 4 h after administration)
Fig. 1 Data of five selected patients: P1 with average parameters; P8, the only patient with a decrease in radiation-induced foci (RIF) directly after the
first time-point; P9, the patient with the highest dose rate at the last time-point; P10, the patient with the highest absorbed dose to the blood at the last time-
point; and P11, the patient with the lowest absorbed dose to the blood at the last time-point. a Absorbed dose to the blood as a function of time. b
Absorbed dose rate as a function of time. c Average number of RIF per cell as function of time (for better clarity a break is inserted in the x axis). d
Average number of RIF per cell as function of the absorbed dose to the blood
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The slope is significantly different from zero (t = 8.011;
Prob>|t| = 2.846E−10). The parameters for the lower (LCL)
and upper (UCL) 95% confidence intervals are LCL = 0.009
and UCL = 0.015 for the slope and LCL = −0.018 and UCL =
0.086 for the intercept. The slope obtained in this work is 17%
smaller than the slope of an in-vitro calibration curve
established for 177Lu and 131I in a previous study [22].
Figure 3b shows the linear in-vitro calibration curve as a
dashed line for comparison.
Dose rate-dependency of the number of RIF per cell
Figure 4a shows the average number of RIF per cell as a
function of the absorbed dose rate dDbldt in all 16 patients.
The average numbers of RIF per cell for the last two
sampling time-points t6 and t7 (with absorbed dose rates
of less than 0.6 mGy h−1) are shown for 13 patients in
more detail in Fig. 4b. The three patients with a missing t7
value (P5, P8 and P12) were excluded from this graph and
analysis. A fit to the pooled data revealed a linear rela-
tionship (R2 = 0.560) between the average number of RIF
per cell and the absorbed dose rate in this range. The
corresponding linear equation is:
Average RIF per Cell
¼ −0:0066  0:0326ð Þ þ 0:6895 0:1248ð Þ h mGy−1  dDbl
dt
ð3Þ
The slope is significantly different from zero (t = 5.525;
Prob>|t| = 1.107E−5). The parameters for the 95% confi-
dence intervals are LCL = 0.432 and UCL = 0.947 for the
slope and LCL = −0.074 and UCL = 0.061 for the inter-
cept. In accordance with this result, there was a significant
correlation between the average number of RIF per cell
and the absorbed dose rate at t6 (Pearson’s r = 0.642;
p = 0.007) and at t7 (Pearson’s r = 0.705; p = 0.007).
Correlations with clinical parameters
To test whether the variability in progression of RIF and the
temporal course of the absorbed dose to the blood among the
patients is linked to clinical parameters, correlation analysis
was performed. However, because only 16 patients were in-
cluded in the study, our results are based on a small amount of
data. In the 13 patients with data for the last time-point t7, there
was a significant positive correlation between the PSA level
before therapy and the absorbed dose rate 96 h after adminis-
tration (Spearman’s ρ = 0.819; p = 0.001). A weaker but still
significant correlation was noted between the PSA level after
therapy and the absorbed dose rate 96 h after administration
(Spearman’s ρ = 0.659; p = 0.014) and between the PSA level
after therapy and the average number of RIF per cell 96 h after
administration (Spearman’s ρ = 0.619; p = 0.024). No signifi-
cant correlations were observed between the number of bone
metastases and the absorbed dose rate or the average number
of RIF at t7. Parameters describing kidney function (creatinine
andMAG3 before therapy) did not correlate with the absorbed
dose rate or the average number of RIF at t7.
Discussion
In the current study, we used the γ-H2AX + 53BP1 DSB fo-
cus assay to investigate the time- and dose-dependency of
DNA DSB induction and repair in blood leucocytes of pros-
tate cancer patients during their first therapy with 177Lu-
PSMA. In general, an increase in the average number of RIF
was observed in the first hours after administration of the
Fig. 3 Average number of RIF per cell as a function of the absorbed dose to the blood. a Overview of all time-points. b Detailed view of the first three
time-points (up to 2.6 h after administration) with a linear fit (solid line) to the pooled data, including a 95% confidence band (grey area). For
comparison, the in-vitro calibration curve for 177Lu and 131I taken from reference [22] is also shown (dashed line)
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radiopharmaceutical, followed by a decrease due to DNA re-
pair. A similar time course was also observed in previous
studies investigating γ-H2AX + 53BP1 focus induction and
repair after radioiodine therapy [9, 15] and peptide receptor
radionuclide therapy with 177Lu-labelled DOTATATE/
DOTATOC [14]. In contrast to external irradiation, as in radi-
ation therapy, internal exposure is characterized by continuous
irradiation with a permanently decreasing dose rate after ad-
ministration of the radionuclide. For this reason, a decrease in
the number of RIF was observed at later time-points, despite
the increasing absorbed dose to the blood. The disappearance
of RIF at later time-points could also have been caused poten-
tially by elimination of damaged cells. However, while high
dose rate acute photon irradiation has been shown to induce
apoptotic cell death in blood samples irradiated ex vivo [24,
25] and in minipigs exposed to partial body γ-irradiation with
50 Gy [23], we only occasionally noted apoptotic leucocytes
in our in-vivo samples exposed to low doses and low dose
rates. Therefore, we consider it unlikely that a preferential
elimination of damaged cells influenced the repair time
courses observed.
In the present study, the mean total absorbed dose to the
blood was 109 ± 29 mGy after administration of 5.9 ±
0.2 GBq. The median absorbed dose to the blood 48 h after
administration was 80 mGy (min 61 mGy; max 144 mGy).
This is comparable with the results of Eberlein et al. who
observed an absorbed dose to the blood of 79 ± 16 mGy
48 h after administration of 7.2 ± 0.4 GBq 177Lu-labelled
DOTATATE/DOTATOC [14]. The total absorbed dose to the
blood could not be calculated by Eberlein et al. since no data
were available for time-points >48 h after administration [14].
Up to 2.6 h after administration (time-points t0, t1 and t2),
there was a linear relationship between the average number of
RIF per cell and the absorbed dose to the blood. A linear
increase in the average number of RIF was also observed in
the first 2 h after administration of 131I [15] and up to 5 h after
administration of 177Lu-DOTATATE/DOTATOC [14]. As in
these previous studies, the slope of the linear curve obtained in
this investigation was less than the slope of the in-vitro cali-
bration curve established for 177Lu and 131I by Eberlein et al.
[22]. Here, the difference to the in-vitro slopes was 17%,while
in the patient studies investigating the induction of RIF after
radioiodine therapy and therapy with 177Lu-DOTATATE/
DOTATOC, the differences between the slopes of the in-
vivo and the in-vitro data were 20% and 14%, respectively
[14, 15]. The slightly shallower slope observed in all patient
studies can be explained by the onset of DNA repair. Another
reason for the differences between the slopes may be the great-
er inaccuracy in the calculation of the absorbed doses for the
early time-points, as the first measurement for activity quan-
tification was taken not earlier than 1 h after administration.
Finally, it is possible that the difference in cellular environ-
ment (redox state) between the systemic in-vivo exposure and
the “artificial” ex-vivo irradiation in blood tubes may have led
to a lower induction of DSBs in patients.
While the average number of RIF per cell correlated with
the absorbed dose to the blood during the first hours after
administration of the radiopharmaceutical, we found that the
absorbed dose rate was the determining factor for RIF pro-
gression at later time-points t6 and t7 (48 h and 96 h after
administration). During the first hours after administration,
no correlation was observed between the absorbed dose rate
and the average number of RIF per cell. For the late time-
points t6 and t7, however, there was a linear relationship be-
tween the dose rate and the average number of RIF per cell.
This indicates that patients with relatively high absorbed dose
rates exhibit either slower focus repair kinetics or an increased
rate of focus induction even at late time-points. An absorbed
dose rate-dependency of RIF was also observed by Lassmann
et al. in patients with differentiated thyroid cancer undergoing
Fig. 4 Average number of RIF per cell as a function of the absorbed dose rate. aOverview of all time-points. bDetailed view of the last two time-points
(48 h and 96 h after administration) with a linear fit (solid line) to the pooled data, including a 95% confidence band (grey area). Only the 13 patients with
data for both time-points were included in the graph and in the fit
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radioiodine therapy [9]. In other studies investigating γ-
H2AX foci after radionuclide therapy [14, 15, 17, 18], an
absorbed dose rate-dependency of RIF was not considered.
For the latest time-points in particular, we also ob-
served a high variability in the data among the patients.
In seven of 13 patients, the number of foci per cell
96 h after administration had decreased to the baseline
values. The other patients still showed elevated numbers
of foci correlating with higher absorbed dose rates at
this time-point.
To find a link between medical parameters and the variable
effectiveness of DNA DSB repair among the patients,
we compared the RIF and dose rate data with clinical
endpoints and found significant correlations with PSA
levels. However, for the correlation analysis only the
data from 13 patients with different pretreatments could
be included. To validate the current findings and to
exclude possible confounding factors, more patients
and data are needed.
Although the general pattern of the time- and dose-
dependencies of RIF induction were similar to those found
in previous studies [14, 15], we observed a higher variability
among the patients overall in this study, which is reflected in a
wider distribution of the foci data and a weaker correlation for
the linear fit as a function of the absorbed dose to the blood for
the first data points. A possible reason for this could be the
comparatively longer medical history and the individual
variability in the extensive pretreatments of the patients.
Other possible causes of the variability among the pa-
tients are variations in the absorbed dose delivery di-
rectly after administration and differences in individual
repair kinetics. In particular at late time-points, repair
kinetics are influenced by varying dose rates. In order
to link the dose-dependency in the first hours after ad-
ministration and the dose rate-dependency for the last
sampling time-points, patient-specific kinetic modelling,
taking into account the dose-dependency of focus induc-
tion and repair, may be applied in future studies.
Conclusion
This is the first study of the induction and persistence of DSB
DNA damage combined with internal dosimetry after therapy
with 177Lu-PSMA. The general pattern of the time-dependent
induction and disappearance of RIF follows that of other ra-
dionuclide therapies. In some patients, RIF had not disap-
peared completely 96 h after administration, which can be
explained by an above average absorbed dose rate. In the
majority of patients, however, the DSBs induced in blood
leucocytes were effectively repaired. The correlation with
clinical findings needs further research in a larger number of
patients.
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